Rights and permissions
About this article
Cite this article
EGFR mutations underlie the responsiveness of NSCLC to gefitinib. Inpharma Wkly. 1451, 11 (2004). https://doi.org/10.2165/00128413-200414510-00027
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200414510-00027